Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MODI-2
- Development stage
- Preclinical
- Lead developer
- Scancell Holdings
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
MODI-2 is a therapeutic cancer vaccine developed by Scancell using its proprietary Moditope® platform. It is designed to target a unique class of post-translational modifications (PTMs) known as homocitrullination, which involves the conversion of lysine residues to homocitrulline. This process is upregulated in the stressed environment of highly immunosuppressed tumors. MODI-2 utilizes the SNAPvax™ technology to co-deliver homocitrullinated peptide antigens alongside TLR-7/8a adjuvants within self-assembling nanoparticles. These nanoparticles are engineered to prime tumor-killing CD4 T cells. The vaccine targets homocitrullinated epitopes derived from several proteins, including vimentin, aldolase, cytokeratin 8, immunoglobulin binding protein (BiP), nucleophosmin (NPM), α-enolase, and heat shock protein (HSP-60). Preclinical studies have demonstrated strong anti-tumor immunity in models of melanoma, colorectal cancer, and breast cancer.
- Other names
- Modi-2Modi2Modi 2
02
Targets
Homocitrullinated Binding immunoglobulin Protein peptideCarb-Vim (Homocitrullinated vimentin peptide)Homocitrullinated aldolase A peptideTLR8 (Toll-like receptor 8)HC-CK8 (Homocitrullinated keratin 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on MODI-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MODI-2.